艾夫他滨 | 181785-84-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 中文名称: 艾夫他滨
• 英文名称: elvucitabine
• 英文别名: β-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine；β-L-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine；4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
• CAS: 181785-84-2
• 化学式: C₉H₁₀FN₃O₃
• 分子量: 227.195
• InChiKey: HSBKFSPNDWWPSL-VDTYLAMSSA-N

物化性质

• 沸点：
  394.9±52.0 °C(Predicted)
• 密度：
  1.66±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-bromophenyl methoxy-alanyl phosphorochloridate 、 艾夫他滨 在 TEA 作用下， 以 二氯甲烷 为溶剂， 以1.1 %的产率得到methyl ((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methoxy)(4-bromophenoxy)phosphoryl)-L-alaninate
  参考文献：
  名称：

  HALO-DEHYDRO-3'-DEOXYURACIL PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

  摘要：

  Substituted halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase activity, and their use in the treatment of medical disorders, such as cancer, are disclosed herein.

  公开号：

  WO2024107850A1
• 作为产物：
  描述：

  (R)-5-{[(tert-butyldiphenylsilyl)oxy]methyl}dihydrofuran-2(3H)-one 在 吡啶 、 4-二甲氨基吡啶 、 三甲基氯硅烷 、 三氟甲磺酸三甲基硅酯 、 triethylamine trihydrofluoride 、 双氧水 、 二异丁基氢化铝 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 44.0h， 生成 艾夫他滨
  参考文献：
  名称：

  Stereoselective Syntheses of β-l-FD4C and β-l-FddC

  摘要：

  Stereocontrolled syntheses of two potent antiviral agents, beta-L-FD4C and beta-L-FddC, were accomplished both in 10-step sequences, with an overall yield of 27% and 25%, respectively. It is worthwhile to mention that the introduction of a phenylseleno moiety to the C-2 alpha position of the lactone 4 can now be performed in a stereocontrolled fashion, providing the key intermediate 5 alpha in 75% yield.

  DOI：

  10.1021/jo970177k

文献信息

• [EN] NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS<br/>[FR] NOUVEAUX NUCLÉOSIDES MODIFIÉS AVEC UN PHOSPHATE, À BASE DE PHOSPH(ON)ATE ET DE SULF(ON)ATE, UTILES COMME SUBSTRATS POUR LES POLYMÉRASES ET COMME AGENTS ANTIVIRAUX
  申请人：UNIV LEUVEN KATH

  公开号：WO2011069688A1

  公开（公告）日：2011-06-16

  This invention provides phosphate-modified nucleosides represented by the structural formula ( I ): wherein W is O or S, and wherein B, R1; R3 and R2. are as defined herein. These compounds are useful as substrates for DNA/RNA polymerases, and as anti-viral agents in particular against HIV-1.

  这项发明提供了由结构式（I）表示的磷酸酯修饰核苷，其中W为O或S，B、R1、R3和R2的定义如本文所述。这些化合物可作为DNA/RNA聚合酶的底物使用，特别是作为抗HIV-1的抗病毒药物。
• NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS
  申请人：Herdewijn Piet

  公开号：US20120245029A1

  公开（公告）日：2012-09-27

  This invention provides phosphate-modified nucleosides represented by the structural formula (I): wherein W is O or S, and wherein B, R 1 ; R 3 and R 2 . are as defined herein. These compounds are useful as substrates for DNA/RNA polymerases, and as anti-viral agents in particular against HIV-1.

  这项发明提供了由结构式(I)表示的磷酸修饰核苷酸，其中W为O或S，而B、R1、R2和R3如此处所定义。这些化合物可作为DNA/RNA聚合酶的底物，特别是在抗击HIV-1方面作为抗病毒剂。
• Novel phosphonic acid based prodrugs of PMEA and its analogues
  申请人：——

  公开号：US20030229225A1

  公开（公告）日：2003-12-11

  Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1 wherein: M and V are cis to one another and MPO 3 H 2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V is selected from a group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF 3 and OR 6 ; R6 is selected from the group consisting of C1-C3 alkyl, and CF 3 ; and pharmaceutically acceptable salts thereof.

  公式I的前药、它们的用途、它们的中间体以及它们的制造方法被描述：其中：M和V相对于彼此是顺式的，MPO3H2是从以下组中选择的膦酸，包括9-(2-膦甲氧基乙基)腺嘌呤，(R)-9-(2-膦甲氧基丙基)腺嘌呤，9-(2-膦甲氧基乙基)鸟嘌呤，9-(2-膦甲氧基乙氧基)腺嘌呤，9-(2-膦甲氧基乙基)-2,6-二氨基嘌呤，(S)-1-(3-羟基-2-膦甲氧基丙基)胞嘧啶，(S)-9-(3-羟基-2-膦甲氧基丙基)腺嘌呤，9-(3-羟基-2-膦甲氧基丙基)鸟嘌呤，以及(S)-9-(3-氟-2-膦甲氧基丙基)腺嘌呤；V从以下组中选择，包括苯基，2-吡啶基，3-吡啶基，4-吡啶基，2-呋喃基，3-呋喃基，2-噻吩基和3-噻吩基，所有这些基可选地被1-3个来自F、Cl、Br、C1-C3烷基、CF3和OR6的基替代；R6从C1-C3烷基和 的组中选择；以及其药学上可接受的盐。
• [EN] METHOD FOR SYNTHESIZING beta-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (beta-L-FD4C)<br/>[FR] PROCEDE DE SYNTHESE DE DOLLAR G(B)-L-5-FLUORO-2',3'-DIDEOXY-2',3'-DIDEHYDROCYTIDINE ( DOLLAR G(B)-L-FD4C)
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2003087119A1

  公开（公告）日：2003-10-23

  The invention provided a method of synthesizing β -L-5-fluoro-2´,3´-dideoxy-2´,3´-didehydrocytidine (β -L-FD4C). The method allows for large-scale production of β -L-FD4C in an efficient, cost-efficient, and environmentally sound manner.

  本发明提供了一种合成β-L-5-氟-2'，3'-二去氧-2'，3'-二脱氢胞苷（β-L-FD4C）的方法。该方法可以以高效、成本效益和环保的方式进行β-L-FD4C的大规模生产。
• [EN] NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS<br/>[FR] NOUVEAUX MÉDICAMENTS ANTI-MYCOBACTÉRIENS CONTRE LA TUBERCULOSE
  申请人：UNIV GEORGIA

  公开号：WO2013148174A1

  公开（公告）日：2013-10-03

  The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.

  本发明涉及抗结核治疗领域，特别是肺部多药耐药结核病（MDR-TB）的治疗，包括广泛耐药结核病（XDR-TB）和极度耐药结核病（XXDR-TB），优选采用联合治疗。